News
NVSEF
136.10
-3.43%
-4.83
Weekly Report: what happened at NVSEF last week (0928-1002)?
Weekly Report · 3d ago
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario
Seeking Alpha · 09/30 17:30
Weekly Report: what happened at NVSEF last week (0921-0925)?
Weekly Report · 09/28 09:26
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
Seeking Alpha · 09/21 21:14
Weekly Report: what happened at NVSEF last week (0914-0918)?
Weekly Report · 09/21 09:26
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Seeking Alpha · 09/18 13:22
Novartis scraps ALS therapy after mid-stage trial setback
Seeking Alpha · 09/16 13:21
Weekly Report: what happened at NVSEF last week (0907-0911)?
Weekly Report · 09/14 09:28
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Seeking Alpha · 09/10 17:38
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Seeking Alpha · 09/08 17:54
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Seeking Alpha · 09/08 14:26
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed
Seeking Alpha · 09/08 13:53
Stock Index Futures Mixed as Oil Nears $100, U.S. Inflation Data Awaited
Barchart · 09/08 05:37
Weekly Report: what happened at NVSEF last week (0831-0904)?
Weekly Report · 09/07 09:26
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Seeking Alpha · 09/04 17:09
Novartis and Alteogen ink injectable drug delivery deal worth up to $3.2B
Seeking Alpha · 09/02 16:47
Novartis: Today's Positive Remibrutinib Data Key To Unlocking Growth Plans
Seeking Alpha · 09/01 19:46
Novartis gains on late-stage trial win for hives therapy in multiple sclerosis
Seeking Alpha · 09/01 12:36
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Seeking Alpha · 08/31 14:50
Weekly Report: what happened at NVSEF last week (0824-0828)?
Weekly Report · 08/31 09:28
More
Webull provides a variety of real-time NVSEF stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVSEF
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.